


## Data Sheet (Cat.No.T16870)

### Selgantolimod

#### Chemical Properties

CAS No.:	2004677-13-6
Formula:	C <sub>14</sub> H <sub>20</sub> FN <sub>5</sub> O
Molecular Weight:	293.34
Appearance:	N/A
Storage:	0-4°C for short term (days to weeks), or -20°C for long term (months).



#### Biological Description

Description	Selgantolimod is an effective and selective toll-like receptor 8 agonists for the treatment of the hepatitis B virus and human immunodeficiency virus infection.
Targets(IC <sub>50</sub> )	TLR8;HBV: None
In vitro	Selgantolimod induces the cellular immune mediators interleukin (IL)-12 and IL-8, as well as the antiviral cytokines tumor necrosis factor- $\alpha$ and interferon- $\gamma$ in vitro in human peripheral blood mononuclear cells. Selgantolimod-induced cytokines reduce HBV DNA, RNA, and antigen levels in HBV-infected primary human hepatocytes. Selgantolimod activates natural killer and mucosal-associated invariant T cells, stimulates cluster of differentiation (CD)-8+ T-cell proliferation, and increase IFN $\gamma$ production while lowering programmed cell death protein 1 expression by HBV-specific CD8+-T cells in vitro in peripheral blood mononuclear cells [1].
In vivo	Selgantolimod (p.o., once-weekly) treatment induces dose-dependent increases in serum IL-12 and IL-1 receptor antagonist (IL-1RA) in cynomolgus monkeys and causes functional cure in the woodchuck model of chronic HBV [1].

#### Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble
------------	---

#### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.409 mL	17.045 mL	34.09 mL
5 mM	0.682 mL	3.409 mL	6.818 mL
10 mM	0.341 mL	1.705 mL	3.409 mL
50 mM	0.068 mL	0.341 mL	0.682 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

1. Jules Levin. Efficacy and Safety of Oral TLR8 Agonist Selgantolimod in Virally Suppressed Adult Patients With Chronic Hepatitis B: a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. 2019 Nov 8-12.
2. Benjamin Ryan. Selgantolimod Shows Promise as Treatment for Hepatitis B. November 18, 2019.
3. Romas Geleziunas, et al. Modulators of toll-like receptors for the treatment of hiv. US20170071944A1.

**Inhibitors · Natural Compounds · Compound Libraries**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street,Wellesley Hills,MA 02481